Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alza’s fentanyl TTS patch

Executive Summary

Received intensive final stage FDA review at "NDA Day" held July 30. Reportedly, the narcotic analgesic patch is expected to be approved within weeks. The NDA, filed in December 1987, has been under the purview of FDA's Pilot Drug Evaluation staff ("The Pink Sheet" May 21, T&G-4). TTS-fentanyl is designed for patients with severe, long-term pain often associated with cancer or for patients with acute postoperative pain. Janssen will market the novel dosage form in the U.S. and other countries. Alza has the right to co-promote TTS-fentanyl to U.S. oncologists.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts